Hospitalizations and Mortality Among Older Adults With and Without Restricted Access to Nirmatrelvir-Ritonavir
Overview
Overview
Journal
JAMA
Publisher
American Medical Association
Specialty
General Medicine
Date
2025 Feb 20
PMID
39976986
Authors
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Maciejewski M, Basu A
. Regression Discontinuity Design. JAMA. 2020; 324(4):381-382.
DOI: 10.1001/jama.2020.3822.
View
2.
Hammond J, Fountaine R, Yunis C, Fleishaker D, Almas M, Bao W
. Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. N Engl J Med. 2024; 390(13):1186-1195.
PMC: 11156287.
DOI: 10.1056/NEJMoa2309003.
View
3.
Chua K, Conti R, Lagisetty P, Bohnert A, He S, Nguyen T
. Association Between Cost Sharing and Naloxone Prescription Dispensing. JAMA. 2024; 332(2):124-132.
PMC: 11177218.
DOI: 10.1001/jama.2024.8378.
View
4.
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W
. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022; 386(15):1397-1408.
PMC: 8908851.
DOI: 10.1056/NEJMoa2118542.
View
5.
Ge E, Li Y, Wu S, Candido E, Wei X
. Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with COVID-19 in Canada: A population-based cohort study. PLoS One. 2021; 16(10):e0258154.
PMC: 8491945.
DOI: 10.1371/journal.pone.0258154.
View